A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

• BGM1812 (Drug): AdministeredSC
• Placebo (Drug): Administered SC
• BGM1812 (Drug): Administered SC
• Placebo (Drug): Administered SC

Primary outcomes

• Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator [Baseline to Study Completion (Up to 6-9weeks)]: Number of participants with AEs and SAEs will be assessed with reference to CTCAE V5.0

Secondary outcomes

• Pharmacokinetic (PK): Maximum Concentration (Cmax) of BGM1812 [Baseline to Study Completion (Up to 6-9weeks)]: PK Cmax of BGM1812
• PK: Area Under the Concentration Versus Time Curve (AUC) of BGM1812 [Baseline to Study Completion (Up to 6-9weeks)]: PK:AUC of BGM1812
• Pharmacodynamics (PD): Fasting Blood Glucose of BGM1812 [Baseline to Study Completion (Up to 6-9weeks)]: PD: Changes in fasting blood glucosebefore and after administration, and differences in the amount of change among different dose groups
• PD:C-Peptide of BGM1812 [Baseline to Study Completion (Up to 6-9weeks)]: PD: Changes in C-peptide before and after administration, and differences in the amount of change among different dose groups
• PD: Insulin of BGM1812 [Baseline to Study Completion (Up to 6-9weeks)]: PD: Changes in insulin before and after administration, and differences in the amount of change among different dose groups
• PD: Body Weight of BGM1812 [Baseline to Study Completion (Up to 6-9weeks)]: PD: Changes in body weight before and after administration, and differences in the amount of change among different dose groupsPD: Changes in body weight before and after administration, and differences in the amount of change among different dose groups
• PD: Waist Circumference of BGM1812 [Baseline to Study Completion (Up to 6-9weeks)]: PD: Changes in waist circumference before and after administration, and differences in the amount of change among different dose groups
• Anti-drug antibodies (ADA) of the study drug and their titers [Baseline to Study Completion (Up to 6-9weeks)]: Detect the anti-drug antibodies (ADA) of the study drug and their titers; if the ADA is positive, neutralizing antibodies (NAb) will be further detected.

Sex: All, ages: 18 Years to 55 Years, accepts healthy volunteers

Inclusion Criteria:

* Between the ages of 18 and 65 years (inclusive) at the time of screening , healthy and non-diabetic overweight or obese subjects , both male and female;
* Healthy subjects , male weight ≥ 50 kg, female weight ≥ 45 kg, and body mass index (BMI): 20.0 kg/m² ≤ BMI < 24 kg/m²（BMI = weight/height²）;
* Obese individuals: BMI ≥ 28.0 kg/m², or overweight individuals: 24.0 kg/m² ≤ BMI < 28.0 kg/m²;
* (Medical Inquiry) Have a stable body weight (<5% self-reported change during the previous 12 weeks) before screening.
* Have no history of mental disorders, be able to communicate smoothly with Investigator, Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.
* Male subjects with female partners of reproductive potential must agree to practice abstinence or to use a condom (male subject) plus an additional medically acceptable form of contraception (female partner) for the duration of the study and for at least 3 months after dosing; must also agree to refrain from sperm donation for at least 3 months post dose.

Exclusion Criteria:

* Those with a history of severe drug allergies (especially those with known or suspected allergies to related compounds of BGM1812), or complicated with severe specific allergic diseases/history, or with a severe allergic constitution.
* Subjects with positive results for HBsAg, anti-HCV, anti-HIV or anti-TP during the screening period.
* 12-lead ECG shows ventricular heart rate < 50 beats/min or > 100 beats/min at screening/baseline, second or third degree atrioventricular block, long QT syndrome, QTcF> 470ms for women or > 450ms for men, pre-excitation syndrome or other significant arrhythmias.
* Used illegal drugs within 6 months prior to screening, or substance abuse within 12 months prior to screening.
* Participated in drug or medical device clinical trials and treated with Study Drug (excluding placebo) or medical device intervention within 12 weeks before screening.
* Participants who have received any vaccine within 2 weeks prior to screening, or plan to receive a vaccine during the trial.
* Female participants who are pregnant or lactating, or those with a positive pregnancy test result during the screening period.
* Positive urine drug test or alcohol serum test result at screening or at baseline.
* Has any other conditions or disorders deemed unsuitable for including in the study, in the opinion of the Investigator.